Drugs / PROSTVAC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00001382 | Mar 1994 → Mar 2000 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04020094 | Nov 2019 → Apr 2021 | prostate adenocarcinoma | University of Utah | Withdrawn | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-09-14 | Bavarian Nordic | Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic’s Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer bavarian-nordic.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PROSTVAC | “Patients will be treated with an intraprostatic injection of MVA-BN-Brachyury and subcutaneous PROSTVAC therapy.” NCT04020094 ↗ |
| Modality | Vaccine | “repeated vaccinations with a recombinant vaccinia virus” NCT00001382 ↗ |
| Route | Other | “2.65 x 10(6) PFU of vaccine by scarification” NCT00001382 ↗ |